- Home
- CR vs EXEL Comparison
CR vs EXEL Comparison
Compare CR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- EXEL
- Stock Information
- Founded
- CR 1855
- EXEL 1994
- Country
- CR United States
- EXEL United States
- Employees
- CR N/A
- EXEL N/A
- Industry
- CR Metal Fabrications
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CR Industrials
- EXEL Health Care
- Exchange
- CR Nasdaq
- EXEL Nasdaq
- Market Cap
- CR 10.9B
- EXEL 12.0B
- IPO Year
- CR N/A
- EXEL 2000
- Fundamental
- Price
- CR $189.04
- EXEL $44.47
- Analyst Decision
- CR Strong Buy
- EXEL Buy
- Analyst Count
- CR 4
- EXEL 18
- Target Price
- CR $197.75
- EXEL $44.24
- AVG Volume (30 Days)
- CR 338.1K
- EXEL 3.6M
- Earning Date
- CR 07-28-2025
- EXEL 07-28-2025
- Dividend Yield
- CR 0.49%
- EXEL N/A
- EPS Growth
- CR 54.50
- EXEL 237.58
- EPS
- CR 5.76
- EXEL 2.20
- Revenue
- CR $2,178,600,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- CR $10.22
- EXEL $9.93
- Revenue Next Year
- CR $10.98
- EXEL $13.17
- P/E Ratio
- CR $32.60
- EXEL $20.18
- Revenue Growth
- CR 17.22
- EXEL 24.49
- 52 Week Low
- CR $127.04
- EXEL $22.20
- 52 Week High
- CR $195.00
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CR 57.88
- EXEL 53.42
- Support Level
- CR $183.50
- EXEL $44.03
- Resistance Level
- CR $190.89
- EXEL $45.52
- Average True Range (ATR)
- CR 4.23
- EXEL 1.44
- MACD
- CR -0.75
- EXEL -0.06
- Stochastic Oscillator
- CR 55.92
- EXEL 22.78
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.